Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway

Acta Pharmacologica Sinica

Volumn 30, Issue 9, 2009, Pages 1316-1322

  Cao, Liang Qi ^a,c   Wang, Xiao Li ^b   Wang, Qian ^a   Xue, Ping ^c   Jiao, Xing Yuan ^c   Peng, He Ping ^c   Lu, Hai Wu ^c   Zheng, Qiang ^c   Chen, Xi Lin ^a   Huang, Xiao Hui ^a   Fu, Xin Hui ^a   Chen, Jing Song ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangzhou Number 8 People Hospital   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Hepatocellular carcinoma; PPAR?; PTEN; Rosiglitazone

Indexed keywords

CYCLOOXYGENASE 2; FLUOROURACIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ROSIGLITAZONE;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIZATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CYCLOOXYGENASE 2; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; PPAR ALPHA; PTEN PHOSPHOHYDROLASE; THIAZOLIDINEDIONES; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

EID: 70349139683     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.119     Document Type: Article

References (36)

1. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator activated receptors. Lancet 1999; 354: 141-148
2. Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator activated receptor gamma. J Pharmacol Exp Ther 1998; 284: 751-759
3. Rumi MA, Sato H, Ishihara S, Kawashima K, Hamamoto S, Kazumori H, et al. Peroxisome proliferator-activated receptor gamma ligand induced growth inhibition of human hepatocellular carcinoma. Br J Cancer 2001; 84: 1640-1647
4. Kern MA, Schubert D, Sahi D, Schöneweiss MM, Moll I, Haugg AM, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002; 36: 885-894
5. Hall AJ, Wild CP. Liver cancer in low and middle income countries. BMJ 2003; 326: 994-995
6. Lee CT, Seol JY, Lee SY, Park KH, Han SJ, Yoo CG, et al. The effect of adenovirus-IkappaBalpha transduction on the chemosensitivity of lung cancer cell line with resistance to cis-diamminedichloroplatinum(II) (cisplatin) and doxorubicin(adriamycin). Lung Cancer 2003; 41: 199-206.
7. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, et al. Coexpression of inducible nitric-oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001; 7: 1325-1332
8. Xue LY, Hu N, Song YM, Zou SM, Shou JZ, Qian LX, et al. Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma. BMC Cancer 2006; 6: 296.
9. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 5405-5412
10. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279
11. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP, et al. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J 2003; 22: 5501-5510
12. Yuan XJ, Whang YE. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD- dependent pathway. Oncogene 2002; 21: 319-327
13. Mathieu A, Remmelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, et al. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-Stransferase-alpha (GST)-alpha, GST-mu, and GST-pi. Cancer 2004; 101: 1908-1918
14. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, et al. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 2008; 68: 1213-1220
15. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30: 3-21.
16. Kase S, Osaki M, Honjo S, Takeda A, Adachi K, Araki K, et al. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res 2004; 23: 301-307
17. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003; 38: 756-768
18. Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006; 43: 134-143
19. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279
20. Shi X, Liu S, Kleeff J, Friess H, Büchler MW. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-362
21. Mader RM, Müller M, Steger GG. Resistance to 5-fluorouracil. Gen Pharmacol 1998; 31: 661-666 (Pubitemid 28520040)
22. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-442 (Pubitemid 34081374)
23. Kondo M, Nagano H, Wada H, Damdinsuren B, Yamamoto H, Hiraoka N, et al. Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clin Cancer Res 2005;11: 1277-1286
24. Date M, Fukuchi K, Morita S, Takahashi H, Ohura K. 15-Deoxydelta12,14- prostaglandin J2, a ligand for peroxisome proliferatorsactivated receptor-gamma, induces apoptosis in human hepatoma cells. Liver Int 2003; 23: 460-466
25. Cao LQ, Chen XL, Wang Q, Huang XH, Zhen MC, Zhang LJ, et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin 2007; 28: 879-887
26. Zhang YQ, Tang XQ, Sun L, Dong L, Qin Y, Liu HQ, et al. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastro enterol 2007; 13: 1534-1540
27. Lee SY, Hur GY, Jung KH, Jung HC, Lee SY, Kim JH, et al. PPAR- gamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 2006; 51: 297-301.
28. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgammaindependent signal pathways. Mol Cancer Ther 2006; 5: 430-437
29. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 2001; 70: 247-279
30. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280: 1614-1617
31. Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53dependent manner. Gynecol Oncol 2006; 102: 348-355
32. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 2007; 42: 93-126.
33. Kase S, Osaki M, Honjo S, Adachi H, Tsujitani S, Kaibara N, et al. Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch 2003; 442: 129-135
34. Honjo S, Osaki M, Ardyanto TD, Hiramatsu T, Maeta N, Ito H, et al. COX-2 inhibitor, NS398, enhances Fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines. DNA Cell Biol 2005; 24: 141-147
35. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-1596
36. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13: 559-583